Current Interview: Professor Nikolaus Rajewsky, Director of the Berlin Institute for Medical Systems Biology at the Max Delbrück Center for Molecular Medicine in Berlin

Nikolaus Rajewsky studied mathematics and physics in his hometown of Cologne. After earning his doctorate, he spent time abroad in New Jersey and New York. In 2006, the 50-year-old returned to Germany and has since been Professor of Systems Biology...

More

Digital Health Summit Berlin

More

ERC Synergy Grant awarded to project exploring playful learning

Implementing a project entitled ‘BrainPlay’, an interdisciplinary team of researchers will explore the way in which play affects the human brain. Researchers from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health (BIH),...

More

Are we immune to the CRISPR-Cas9 gene editing scissors?

The CRISPR-Cas9 gene editing system has been generating excitement within the field of gene therapy, inspiring hopes of molecular tools capable of treating genetic diseases. By studying immune responses to CRISPR-Cas9 in humans, researchers from...

More

Clariness today announced it has acquired Viomedo, a leading online platform for clinical trials and provider of patient enrollment services


Over the last 13 years, Clariness has built a patient recruitment business covering 45 countries and 8 of
the top 10 pharmaceutical companies. “Clinical trials face increasing challenges in terms of cost and
timelines. Clariness strives to drive...

More

Layer-by-Layer nanoscale coatings, surface modification, micro encapsulation and bead based microsensors (pH, temperature, oxygen, chloride, bioanalysis) for co-development of innovative applications

The German SME focuses on three technologies in the field of nanotechnology and biotechnology: tailored surface modification and encapsulation mainly by the Layer-by-Layer (LbL) technology platform; bead-based microsensors for bioanalysis; and...

More

Rapid and Specific Detection of most common Fungal Nail and Skin Infections

Reference Number TO 32-00053

More

FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome

Myelo Therapeutics GmbH announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 for the treatment of Acute Radiation Syndrome (ARS).

More

Preventing Vascular Calcification in Chronic Kidney Disease

Reference Number TO 32-00049

More

Adrenomed closes € 24 M financing led by Wellington and HBM

  • The financing round was led by top-tier life science venture capitalists Wellington Partners and HBM Healthcare Investments, joined by existing shareholders
  • The new funds will be used to execute a proof-of-concept clinical program of lead product...
More
Show more items